COVID-19-Associated Mucormycosis (CAM): An Updated Evidence
Mapping

J 2021

COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping

HUSSAIN, Mohammad Salman, Harveen BAXI, Abanoub RIAD, Jitka KLUGAROVÁ, Andrea POKORNÁ et. al.

Základní údaje

Originální název

COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping

Autoři

HUSSAIN, Mohammad Salman (356 Indie, domácí), Harveen BAXI, Abanoub RIAD (818 Egypt, domácí), Jitka KLUGAROVÁ (203 Česká republika, domácí), Andrea POKORNÁ (203 Česká republika, domácí), Simona SLEZÁKOVÁ (203 Česká republika, domácí), Radim LÍČENÍK (203 Česká republika, domácí), Abul Kalam NAJMI a Miloslav KLUGAR (203 Česká republika, garant, domácí)

Vydání

Environmental Research and Public Health, Basel, MDPI, 2021, 1660-4601

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30304 Public and environmental health

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.614

Kód RIV

RIV/00216224:14110/21:00122477

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/ijerph181910340

UT WoS

000707124900001

Klíčová slova anglicky

COVID-19; diabetes; epidemiology; evidence; mortality; mucormycosis; mycoses; public health

Štítky

14110525, 14110611, 14119612, 14119613, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 5. 2022 10:41, Mgr. Tereza Miškechová

Anotace

V originále

Mucormycosis, a serious and rare fungal infection, has recently been reported in COVID-19 patients worldwide. This study aims to map all the emerging evidence on the COVID-19-associated mucormycosis (CAM) with a special focus on clinical presentation, treatment modalities, and patient outcomes. An extensive literature search was performed in MEDLINE (Ovid), Embase (Ovid), Cochrane COVID-19 Study Register, and WHO COVID-19 database till 9 June 2021. The primary outcome was to summarize the clinical presentation, treatment modalities, and patient outcomes of CAM. Data were summarized using descriptive statistics and presented in tabular form. This evidence mapping was based on a total of 167 CAM patients with a mean age of 51 ± 14.62 years, and 56.28% of them were male. Diabetes mellitus (73.65% (n = 123)), hypertension (22.75% (n = 38)), and renal failure (10.77% (n = 18)) were the most common co-morbidities among CAM patients. The most common symptoms observed in CAM patients were facial pain, ptosis, proptosis, visual acuity, and vision loss. Survival was higher in patients who underwent both medical and surgical management (64.96%). Overall mortality among CAM patients was found to be 38.32%. In conclusion, this study found a high incidence of CAM with a high mortality rate. Optimal glycemic control and early identification of mucormycosis should be the priority to reduce the morbidity and mortality related to CAM.

Návaznosti

EF18_053/0016952, projekt VaV

Název: Postdoc2MUNI

LTC20031, projekt VaV

Název: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST

MUNI/A/1608/2020, interní kód MU

Název: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III

Investor: Masarykova univerzita, Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III

MUNI/IGA/1543/2020, interní kód MU

Název: Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic (Akronym: Evidence-Based Practice in Czechia)

Investor: Masarykova univerzita, Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic

Citovat

HUSSAIN, Mohammad Salman, Harveen BAXI, Abanoub RIAD, Jitka KLUGAROVÁ, Andrea POKORNÁ, Simona SLEZÁKOVÁ, Radim LÍČENÍK, Abul Kalam NAJMI a Miloslav KLUGAR. COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping. Environmental Research and Public Health. Basel: MDPI, 2021, roč. 18, č. 19, s. 1-18. ISSN 1660-4601. Dostupné z: https://dx.doi.org/10.3390/ijerph181910340.

@article{1795084,
   author = {Hussain, Mohammad Salman and Baxi, Harveen and Riad, Abanoub and Klugarová, Jitka and Pokorná, Andrea and Slezáková, Simona and Líčeník, Radim and Najmi, Abul Kalam and Klugar, Miloslav},
   article_location = {Basel},
   article_number = {19},
   doi = {http://dx.doi.org/10.3390/ijerph181910340},
   keywords = {COVID-19; diabetes; epidemiology; evidence; mortality; mucormycosis; mycoses; public health},
   language = {eng},
   issn = {1660-4601},
   journal = {Environmental Research and Public Health},
   title = {COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping},
   url = {https://www.mdpi.com/1660-4601/18/19/10340},
   volume = {18},
   year = {2021}
}

TY  - JOUR
ID  - 1795084
AU  - Hussain, Mohammad Salman - Baxi, Harveen - Riad, Abanoub - Klugarová, Jitka - Pokorná, Andrea - Slezáková, Simona - Líčeník, Radim - Najmi, Abul Kalam - Klugar, Miloslav
PY  - 2021
TI  - COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping
JF  - Environmental Research and Public Health
VL  - 18
IS  - 19
SP  - 1-18
EP  - 1-18
PB  - MDPI
SN  - 16604601
KW  - COVID-19
KW  - diabetes
KW  - epidemiology
KW  - evidence
KW  - mortality
KW  - mucormycosis
KW  - mycoses
KW  - public health
UR  - https://www.mdpi.com/1660-4601/18/19/10340
N2  - Mucormycosis, a serious and rare fungal infection, has recently been reported in COVID-19 patients worldwide. This study aims to map all the emerging evidence on the COVID-19-associated mucormycosis (CAM) with a special focus on clinical presentation, treatment modalities, and patient outcomes. An extensive literature search was performed in MEDLINE (Ovid), Embase (Ovid), Cochrane COVID-19 Study Register, and WHO COVID-19 database till 9 June 2021. The primary outcome was to summarize the clinical presentation, treatment modalities, and patient outcomes of CAM. Data were summarized using descriptive statistics and presented in tabular form. This evidence mapping was based on a total of 167 CAM patients with a mean age of 51 ± 14.62 years, and 56.28% of them were male. Diabetes mellitus (73.65% (n = 123)), hypertension (22.75% (n = 38)), and renal failure (10.77% (n = 18)) were the most common co-morbidities among CAM patients. The most common symptoms observed in CAM patients were facial pain, ptosis, proptosis, visual acuity, and vision loss. Survival was higher in patients who underwent both medical and surgical management (64.96%). Overall mortality among CAM patients was found to be 38.32%. In conclusion, this study found a high incidence of CAM with a high mortality rate. Optimal glycemic control and early identification of mucormycosis should be the priority to reduce the morbidity and mortality related to CAM.
ER  -

HUSSAIN, Mohammad Salman, Harveen BAXI, Abanoub RIAD, Jitka KLUGAROVÁ, Andrea POKORNÁ, Simona SLEZÁKOVÁ, Radim LÍČENÍK, Abul Kalam NAJMI a Miloslav KLUGAR. COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping. \textit{Environmental Research and Public Health}. Basel: MDPI, 2021, roč.~18, č.~19, s.~1-18. ISSN~1660-4601. Dostupné z: https://dx.doi.org/10.3390/ijerph181910340.

Podrobný výpis o publikaci